Who is the CEO of ImmunoGen, Inc.?

Mr. Mark Joseph Enyedy is a business executive who currently serves as the CEO of ImmunoGen, Inc..

What is the Revenue Growth of ImmunoGen, Inc.?

Revenue growth data for ImmunoGen, Inc. is currently unavailable.

What is ImmunoGen, Inc. operating Margin?

ImmunoGen, Inc. operating margin is 11.07% which shows how much profit 0A8K.L earns from each dollar of sales, after subtracting the direct costs tied to generating that revenue.

In which market sector does ImmunoGen, Inc. operate?

ImmunoGen, Inc. falls under the Healthcare sector which thrives across multiple industries. It stays competitive through its diverse product lineup, which spans computer hardware, tech gadgets, video streaming services, and cloud computing solutions.

What is ImmunoGen, Inc. revenue growth?

Revenue growth data for ImmunoGen, Inc. is currently unavailable.

ImmunoGen, Inc.

0A8K.L•LSE

HealthcareBiotechnology

$31.24

$0.01(0.03%)

ImmunoGen, Inc. (0A8K.L) Stock Overview

Explore ImmunoGen, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for 0A8K.LStats details for 0A8K.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations data is not available for 0A8K.LAnalyst Recommendations details for 0A8K.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

CEO

Mr. Mark Joseph Enyedy

Employees

277

Headquarters

830 Winter Street, Waltham, MA

Founded

2021